Quanterix Appoints William Geist as Chief Operating Officer Geist brings operational experience to Quanterix as the company scales to support rapid growth and commercial success Billerica, Mass.

Quanterix Appoints William Geist as Chief Operating Officer

brings operational experience to Quanterix as the company scales to support rapid growth and commercial success

Billerica, Mass. - November 18, 2020 - Quanterix

Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced

it has named William Geist to the position of chief operating officer (COO), effective November 16, 2020.

"Quanterix is experiencing strong momentum across numerous

digital biomarker platforms supporting drug development and non-invasive, early disease diagnostics research," said Kevin

Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix. "We are extremely fortunate to attract Will into Quanterix

at this important time given his wealth of operating experience and track record for growing revenue and profitability, both commercially

Geist brings over 25 years of experience to Quanterix, most

recently serving as vice president and general manager for two of Thermo Fisher Scientific's largest business units: Protein

and Cell Analysis (PCA) and qPCR. He also served a key leadership role in Thermo Fisher Scientific's Biosciences Division

COVID-19 Task Force. Prior to joining Thermo Fisher Scientific, Geist held numerous sales, marketing and business development leadership

roles, including vice president of sales, marketing and business development at QIAGEN's Quanta BioSciences. He holds a B.A.

in Biology from Dartmouth College.

In his role, Geist will build on Quanterix' track record

of strong execution as the Company expands globally and continues to disrupt pharmaceutical development and diagnostics research.

Will's focus will be on execution and continued growth of the Company's ultrasensitive Simoa technology, including

its groundbreaking neurology franchise, as well as opportunities in COVID, Infectious Disease, Immunology and Oncology.

"I am very excited to join Quanterix during this

phase of growth and expansion," said Geist. "I have long admired the company's mission and execution and

welcome the opportunity to further operationalize and scale the innovation Quanterix continues to achieve as part of its

vision for precision health."

For more information on Quanterix please visit: www.quanterix.com

Quanterix is a company that's digitizing biomarker analysis

with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential

to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from

health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced

treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently

being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and

infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information,

please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect,"

"plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words

or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking

statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release.

Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results

to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix'

filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except

as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change

in expectations, even as new information becomes available.

Staci Didner, 407 734 7325

Investor Relations Contact: